Rail Vision Receives Purchase Order from One of the Leading Central America Freight Rail Operators
Ra’anana, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN) (the “Company”), a technology company at the […]
High Roller Technologies Welcomes Kristofer Muscat as Chief Operating Officer
Las Vegas, Nevada, Jan. 10, 2025 (GLOBE NEWSWIRE) — High Roller Technologies, Inc. (“High Roller” and the “Company”) (NYSE American: […]
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and […]
BTCS Launches Innovative Staker Protection Plan
Silver Spring, MD, Jan. 10, 2025 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a leader in […]
OrthoPediatrics Corp. Announces Expansion of Specialty Bracing Division
WARSAW, Ind., Jan. 10, 2025 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively […]
Volcon MN1 Unit Arrives at Cycle Plaza Corpus Christi, Ready to Sell
AUSTIN, Texas, Jan. 10, 2025 (GLOBE NEWSWIRE) — Volcon ePowersports (NASDAQ: VLCN) is proud to announce that the Volcon MN1 […]
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over […]
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
– Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of […]
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing […]
Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement
Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 million Placement at A$0.060 per share, representing a premium of 150% […]
